Navigation Links
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
Date:11/12/2013

al and administrative expenses for the first nine months of 2013 were $24.6 million, compared to $18.9 million in the same period of 2012. Selling expenses as a percentage of 2013 nine months regular product sales was 31.6%, compared to 33.5% of the same period of last year. The decrease in selling expense as a percentage of regular product sales was mainly due to the higher sales achieved without significantly increasing the sales team headcount and salaries. G&A expenses in the first nine months of 2013 increased to $10.0 million from $8.9 million in the same period of last year. The factors affecting general and administrative expenses in the nine months of 2013 were the same as for the third quarter of 2013 as described above.

Research and development expenses for the first nine months of 2013 decreased to $5.9 million from $15.8 million in the same period of last year as the phase III study of EV71 vaccine candidate was completed in the first quarter of 2013.

Depreciation of property, plant and equipment and amortization of licenses, permits and renovation costs in the first nine months of 2013 was $2.1 million, compared to $1.1 million in the same period of last year. Depreciation increased because more assets at the Changping facility started to be depreciated in the last quarter of 2012.

Net income attributable to stockholders in the first nine months of 2013 was $1.6 million, or $0.03 per basic and diluted share, compared to a net loss of $10.2 million, or $0.19 per basic and diluted share, in the same period of last year. If the $1.7 million bonus, settled from an accrued liability account, was charged to operations for the nine-month period, the net loss of the first nine months of 2013 was $0.1 million, or $0.002 per basic share and diluted share.

As of September 30, 2013, cash and cash equivalents totaled $89.0 million, compared to $91.2 million as of December 31, 2012. Net cash used in operating activities was $14.7 mill
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
4. Sinovac Schedules 2012 Annual Meeting of Shareholders
5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
(Date:7/11/2014)... 2014 Utilizing the Keller Funnel, ... Koenig, has topped a record number of complication-free breast ... over 400 successful procedures without the occurrence of a ... known across the country for his expertise with the ... long been the foundation for numerous studies and research. ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- U.S. health officials have ... exposed to live anthrax during a safety mishap last ... and Prevention officials have announced a moratorium on the ... government labs. In a report issued Friday, the ... make sure a similar incident doesn,t occur again. Last ...
(Date:7/11/2014)... July 11, 2014 According to a ... Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, ... Industrial, Automotive & Transportation, Agriculture) & Geography - Global ... of Internet of Things market was worth $1029.5 Billion ... by 2020, at an estimated CAGR of 4.08% from ...
(Date:7/11/2014)... As reported by the New York Times ... number of severe adverse events such as renal failure, ... from the highly-promoted and costly immune-system drug, Acthar, have ... , a regulatory filing revealed that the total number ... 14% of prescriptions, up from 9.1% in 2011. Specifically, ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... the Canadian Institute for Health Information (CIHI) said that ... there has been no shortening of waiting time. // ... the volume of diagnostic tests and high-priority procedures has ... to have increased just as much. Statistics show that ...
... new University of Toronto study by Professor David Jenkins ... as soy protein, almonds, plant sterol margarines, oats and ... than being eaten in isolation. ,The study is ... of the study was that among the subjects who ...
... of Cornell University research psychologists have found that different ... ,This mainly depends upon the emotions attached ... the help of golden hamsters. They allowed these hamsters ... for evidence of those encounters. ,They identified ...
... Agency (HIRA) found that hospitals had overcharged their patients ... had received a total of 11,139 complaints last year ... Following this they analyzed medical institutions' requests for insurance ... of Health and Welfare. ,It was found ...
... then do a rethink as a new study states that even ... healthy. // ,The bone of contention is cholesterol: HDL ... ,Exercise is known to higher levels of good cholesterol and ... finding in the study was that LDL cholesterol levels in thin ...
... signal for the Chennai-based Shasun Chemicals and Drugs Ltd ... the European markets soon. // ,With the ... Agency (MHRA), Shasun's products from its formulation facility in ... European countries. ,Shasun's plant at Pondicherry, set ...
Cached Medicine News:Health News:Try a consortia of cholesterol-lowering foods for best results 2Health News:Cure For Autism Could Be Established Through Hamster Studies 2
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Laser System features a patented technique for ... It selectively targets pigmented cells and increases ... II is equipped with a Q-switch that ... which induces the same cell replacement mechanism ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: